New product: Poteligeo (mogamulizumab) 4 mg/mL, Concentrate for Solution for Infusion
Mogamulizumab is licensed for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS), who have received at least one prior systemic therapy.
Source:
electronic Medicines compendium